Clazakizumab
Chemical compound
- none
- investigational
- 1236278-28-6
- none
- 4S38Z8RA9O
- D10312
Clazakizumab (formerly ALD518 and BMS-945429), an investigational drug, is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6.[1] Clazakizumab was developed by Bristol Myers Squib and Alder Biopharmaceuticals. A preliminary randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of clazakizumab in psoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a dose-response effect.[2]
See also
- Tocilizumab (Actemra) an anti-IL-6 receptor mAb
- Anti-IL-6, other anti-interleukin-6 agents
References
- ^ Handbook of Therapeutic Antibodies, Volume 2. Wiley Blackwell. 2007. p. 987. ISBN 9783527329373. Retrieved January 23, 2017.
- ^ Mease PJ, Gottlieb AB, et al. (September 2016). "The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis". Arthritis Rheumatol. 68 (9): 2163–73. doi:10.1002/art.39700. PMID 27059799. S2CID 3644962.
- v
- t
- e
Monoclonal antibodies for the immune system
| Human | |
|---|---|
| Humanized | |
| Veterinary |
| Mouse |
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
